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Introduction
Eukaryotic cell membranes contain functional microdomains
of particular lipid and protein composition, the most
characterized of these microdomains being commonly referred
to as lipid rafts (Munro, 2003; Simons and Ehehalt, 2002;
Simons and Ikonen, 1997). Lipid rafts differ from other parts
of the plasma membrane by their high content of cholesterol
and sphingolipids, and are thought to act as platforms
coordinating signal transduction events. Membrane cholesterol
plays a crucial role during infection by some intracellular
pathogens, including bacteria, viruses, protozoans and non-
conventional infectious agents, and studies have indicated an
involvement of lipid rafts in infection by some of these
pathogens (reviewed by Manes et al., 2003; Simons and
Ehehalt, 2002). It is now clear that cell membranes contain
microdomains distinct from conventional lipid rafts, including
a particular type of microdomains enriched in tetraspanins.
Tetraspanins are integral membrane proteins sharing a common
structure with four transmembrane domains delimiting two
extracellular domains of unequal size and three short
intracellular regions. Tetraspanins have been implicated in
various biological processes such as cell adhesion, migration,
cell fusion, co-stimulation, signal transduction and
differentiation (reviewed by Boucheix and Rubinstein, 2001;
Hemler, 2003; Levy and Shoham, 2005), yet their precise
function remains unknown. A current model is that
tetraspanins function as molecular organizers of membrane
multi-molecular complexes, collectively referred to as the
tetraspanin web (Rubinstein et al., 1996). Within this network
of interactions, tetraspanins form primary complexes with a
limited number of proteins called tetraspanin partners. These
tetraspanin-partner interactions are direct and highly specific.
For example, integrins 61 and 31 directly associate with
CD151 but not with other tetraspanins (Serru et al., 1999;
Yauch et al., 1998), whereas CD9P-1 and EWI-2 associate only
with CD9 and CD81 (Charrin et al., 2003a; Charrin et al., 2001;
Clark et al., 2001; Stipp et al., 2001a; Stipp et al., 2001b).
These primary interactions resist detergents such as digitonin
(and in some cases Triton X-100), and typically occur at a high
stoichiometry (Charrin et al., 2003a; Charrin et al., 2001; Serru
et al., 1999; Stipp et al., 2001a; Stipp et al., 2001b; Yauch et
al., 1998). Tetraspanins also interact with each other, building
Tetraspanins constitute a family of widely expressed
integral membrane proteins that associate extensively with
one another and with other membrane proteins to form
specific membrane microdomains distinct from
conventional lipid rafts. So far, because of the lack of
appropriate tools, the functionality of these microdomains
has remained largely unknown. Here, using a new
monoclonal antibody that only binds to the tetraspanin
CD81 associated with other tetraspanins, we show that
membrane cholesterol contributes to the organization of
tetraspanin microdomains on the surface of live cells.
Furthermore, our data demonstrate involvement of host
membrane cholesterol during infection by Plasmodium
yoelii and Plasmodium falciparum sporozoites, which both
depend on host CD81 expression for invasion, but not
during CD81-independent infection by Plasmodium berghei
sporozoites. Our results unravel a functional link between
CD81 and cholesterol during infection by malaria
parasites, and illustrate that tetraspanin microdomains
constitute a novel type of membrane microdomains that
could be used by pathogens for infection.
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specific proteo-lipidic membrane microdomains to which they
probably target their partner proteins (Boucheix and
Rubinstein, 2001; Charrin et al., 2003b; Charrin et al., 2003c;
Hemler, 2003; Levy and Shoham, 2005). In this regard,
tetraspanins colocalize with gangliosides (Claas et al., 2001;
Delaguillaumie et al., 2004; Odintsova et al., 2003), notably
CD9, which directly interacts with GM3 (Ono et al., 2001), and
several tetraspanins directly interact with membrane
cholesterol (Charrin et al., 2003c). Furthermore, a substantial
fraction of tetraspanin complexes can be recovered in the low
density fractions of isopycnic sucrose gradients (Charrin et al.,
2003b; Claas et al., 2001; Delaguillaumie et al., 2004).
Tetraspanin microdomains are typically disrupted by Triton X-
100, but are retained in less hydrophobic detergents such as
Brij 97 (Charrin et al., 2003b). Several studies have
documented key differences between tetraspanin
microdomains and lipids rafts (Charrin et al., 2003b; Charrin
et al., 2003c; Claas et al., 2001; Hemler, 2003).
There are some lines of evidence indicating a role of
tetraspanins during infection by pathogens. For instance,
infection by some viruses can be specifically blocked by
antibodies to certain tetraspanins, including human T cell
leukemia virus 1 by anti-CD81 and anti-CD82 antibodies (Imai
and Yoshie, 1993), canine distemper virus and feline
immunodeficiency virus by anti-CD9 antibodies (Loffler et al.,
1997; Willett et al., 1997), and human immunodeficiency virus
1 by anti-CD63 antibodies (von Lindern et al., 2003).
Additionally, the tetraspanin CD81 is required for infection of
hepatocytes by hepatitis C virus (HCV), and functions as a
receptor for HCV envelope glycoprotein E2, at least for certain
viral strains (Bartosch et al., 2003; Pileri et al., 1998; Zhang et
al., 2004). Recently, we reported that CD81 is also required for
infection by Plasmodium, the parasite responsible for malaria.
Plasmodium sporozoites are transmitted by infected Anopheles
mosquitoes, and first infect the host hepatocytes by forming a
parasitophorous vacuole where they further differentiate into a
replicative exo-erythrocytic form (EEF). We have shown that
CD81 is required for invasion of hepatocytes by sporozoites of
human malaria Plasmodium falciparum and rodent malaria
Plasmodium yoelii parasites (Silvie et al., 2003). Indeed, P.
yoelii sporozoites fail to infect CD81-deficient mouse
hepatocytes, and anti-CD81 antibodies inhibit P. yoelii and P.
falciparum sporozoite invasion of hepatocytes. However, we
found no evidence that CD81 interacts directly with
Plasmodium sporozoites, suggesting that CD81 does not act as
a receptor for the parasite but, rather, is involved indirectly
(Silvie et al., 2003).
The aim of this study was to investigate the mechanisms
underlying tetraspanin microdomain assembly and to
determine the functionality of these microdomains with respect
to Plasmodium sporozoite invasion. So far, these aspects have
remained poorly understood, primarily because of a lack of
appropriate tools, including mAbs specific for microdomain-
associated tetraspanins and reagents able to disrupt tetraspanin
microdomains in live cells.
Results
Generation of two new anti-mouse CD81 mAbs
In an effort to develop new tools to characterize tetraspanin
microdomains, we generated rat mAbs against mouse
tetraspanin complexes, and screened the hybridomas by
indirect immunofluorescence and co-immunoprecipitation
using Brij 97 lysates of biotin-labeled cells. Because lysis in
Brij 97 preserves tetraspanin-tetraspanin interactions, any anti-
tetraspanin mAb can co-immunoprecipitate the entire set of
proteins present in tetraspanin microdomains, yielding
complex and very similar patterns of co-immunoprecipitated
proteins. The tetraspanin pattern obtained with the mouse
hepatoma cell line Hepa1-6 using a CD9 mAb for
immunoprecipitation is shown in Fig. 1. The major proteins co-
immunoprecipitated with CD9 have an apparent molecular
mass consistent with that of  integrin, CD9P-1 and EWI2. We
selected two mAbs, MT81 and MT81w (for mouse tetraspanin
CD81 ‘web’), which gave a pattern very similar to that of CD9,
and clearly different from the pattern obtained with a mAb to
5 integrin, which does not associate with tetraspanins (Fig.
1). This pattern strongly suggested that MT81 and MT81w
were anti-tetraspanin antibodies, and additional experiments
demonstrated that MT81 and MT81w are both anti-mouse
CD81 antibodies. First, MT81 and MT81w labeled the surface
of embryonic fibroblasts from wild-type and CD9-deficient
mice, but not from CD81-deficient mice (Fig. 2, upper panels).
Second, MT81 and MT81w labeling of Hepa1-6 could be
specifically knocked-down by siRNA-mediated silencing of
CD81 (Fig. 2, middle panels). We were concerned that MT81
and MT81w could recognize a mouse molecule that associates
with CD81 and the expression of which depends on the
expression of CD81, as described for CD19 in B lymphoid
cells (Shoham et al., 2003). To rule out this possibility, we
tested MT81 and MT81w reactivity on human HeLa cells
transfected with a mouse CD81 cDNA construct, in
comparison with control HeLa cells, which express only the
endogenous human CD81. Both MT81 and MT81w bound to
mouse CD81-transfected HeLa but not to mock-transfected
HeLa cells (Fig. 2, lower panels), implying that these mAbs do
not recognize human CD81 or a human CD81-associated
protein, but are actual anti-mouse CD81 antibodies. Additional
experiments revealed that MT81 but not MT81w could bind to
a soluble form of mouse CD81 large extracellular domain in
ELISA (data not shown), and react with CD81 in western
blotting conditions (Fig. 4 and data not shown).
Fig. 1. Generation of new mAbs against mouse tetraspanin
complexes. Biotin-labeled Hepa1-6 cells were lysed in 1% Brij 97
before immunoprecipitation with the anti-mouse CD9 mAb 4.1F12
(CD9), with the mAbs MT81 and MT81w, or with an anti-5
integrin mAb (5-int.).
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MT81w recognizes a subset of CD81 molecules
associated with tetraspanin microdomains
As shown by flow cytometry analysis, the intensity of labeling
with MT81w only reached 40-60%, depending on the
experiment, of the intensity of labeling with MT81 on Hepa1-
6 cells (Fig. 3), suggesting that MT81w may recognize only a
subset of CD81 molecules. To further characterize this subset,
we analyzed the ability of MT81w to immunoprecipitate CD81
from cell lysates made under different detergent conditions,
using MT81 as a control anti-CD81 antibody. Western blot
analysis of immunoprecipitates showed that MT81 could
precipitate CD81 under all detergent conditions tested (Fig.
4A). By sharp contrast, MT81w was able to precipitate CD81
only from Brij 97 and CHAPS lysates, both detergents
preserving tetraspanin-tetraspanin interactions, but not from
digitonin and Triton X-100 lysates (Fig. 4A). These latter
conditions prevent tetraspanin-tetraspanin interactions, as
confirmed by the absence of CD81 in the CD9
immunoprecipitate, and reciprocally by the absence of CD9 in
the CD81 immunoprecipitate. These results suggest that
MT81w binds only to CD81 associated with other tetraspanins.
To provide further evidence in favor of this hypothesis, we
performed experiments where cells were lysed in 1% Brij 97
(to preserve tetraspanin-tetraspanin interactions) followed by
Journal of Cell Science 119 (10)
depletion of tetraspanin complexes by successive rounds of
pre-clearing with the anti-CD9 mAb 4.1F12.
Immunoprecipitation with MT81, MT81w and 4.1F12 were
then performed and analyzed by western blot. Complete CD9
depletion was confirmed by the absence of CD9 in the lysates
Fig. 2. MT81 and MT81w are anti-mouse CD81 mAbs. Flow
cytometry analysis of different cell types stained with the mAbs
MT81 (left panels) and MT81w (right panels). Upper panels:
Embryonic fibroblasts from wild-type (wt), CD81 knockout (Cd81–/–,
thick line) or CD9 knockout (Cd9–/–) mice. The labeling of Cd81–/–
cells with mAbs MT81 and MT81w was the same as the control
staining. Middle panels: Hepa1-6 cells transfected with a siRNA
oligonucleotide targeting CD81 (siCD81, thick line) or with a control
siRNA (cont, thin line). Lower panels: HeLa cells transfected with a
mouse CD81 cDNA (mCD81, thick line) or with the vector alone
(mock, thin line). The thin gray line represents the control staining.
Fig. 3. Binding of MT81 and MT81w mAbs to Hepa1-6 cells.
Hepa1-6 cells labeled with increasing concentrations of mAbs MT81
(solid squares) and MT81w (open squares) were analyzed by flow
cytometry. Results are expressed as the mean fluorescence intensity
(MFI) as a function of mAb concentration.
Fig. 4. MT81w only binds to CD81 associated with tetraspanins.
(A) Hepa1-6 cells were lysed in the presence of CHAPS, Brij 97,
digitonin or Triton X-100 before immunoprecipitation with the anti-
CD81 mAbs MT81 and MT81w or with the anti-CD9 mAb 4.1F12.
Immunoprecipitates were analyzed by western blotting using biotin-
labeled anti-CD81 (MT81) and anti-CD9 (4.1F12) mAbs. Note that
MT81w precipitates both CD81 and CD9 in CHAPS and Brij 97, but
not in digitonin or Triton X-100. (B) Hepa1-6 cells were lysed in 1%
Brij 97 before five rounds of immunoprecipitation with anti-CD9
mAb 4.1F12 to deplete CD9 (depl. +) or with beads alone as a
control (depl. –). The supernatants were then used for
immunoprecipitations as in A. The membranes in each panel were
given the same exposure.
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(Fig. 4B). Strikingly, CD9 depletion induced a dramatic
reduction (~85%, as determined by densitometry) of CD81
recovered by MT81 (Fig. 4B, upper left panel). This indicates
that in Hepa1-6 cells a major fraction of the CD81 molecules
is engaged in tetraspanin microdomains. Moreover, CD9
depletion completely removed the pool of CD81 molecules
recognized by MT81w (Fig. 4B, upper middle panel),
confirming that MT81w essentially recognizes CD81
associated with tetraspanins in tetraspanin microdomains.
CD81 localization into cell surface tetraspanin
microdomains depends on cholesterol.
Since MT81w binds only to CD81 associated with other
tetraspanins, this mAb constitutes a valuable tool not only to
evaluate the level of association of CD81 on live cells, but also
to dissect the mechanisms underlying tetraspanin-tetraspanin
interactions. We have previously shown that tetraspanins
interact with cholesterol, as indicated by the labeling of the
tetraspanins CD9, CD81 and CD82 with photoactivatable
cholesterol and by precipitation of tetraspanins by digitonin,
which forms insoluble complexes with cholesterol (Charrin et
al., 2003c). We performed digitonin-precipitation experiments
in Hepa1-6 cells, using MT81w as a marker for CD81
association with tetraspanins. Treatment of Brij 97 lysates with
digitonin resulted in a dramatic reduction in the amount of
CD81 that could be recovered by MT81w in the soluble
fraction, as compared with MT81, whereas
immunoprecipitation of 5 integrin (used as a control) was not
affected by digitonin precipitation (Fig. 5). This result, together
with the fact that digitonin precipitates tetraspanins only under
conditions preserving their mutual interaction (Charrin et al.,
2003c), shows that digitonin preferentially precipitates
tetraspanins associated with each other, and supports the idea
that association of tetraspanins with cholesterol is concomitant
with the formation of tetraspanin-tetraspanin complexes.
We then used MT81w as a tool to directly evaluate, through
a non-biochemical approach, the role of cholesterol in the
organization of tetraspanin microdomains on intact cells. We
used methyl- cyclodextrin (MCD), a cyclic oligosaccharide
that selectively removes cholesterol from the cell plasma
membrane without incorporating into the membrane (Yancey
et al., 1996). Hepa1-6 cells were treated with MCD before
analysis of CD81 and CD9 expression by immunofluorescence
on fixed monolayers. Treatment of Hepa1-6 cells with MCD
decreased the cell cholesterol content by 44±5%, consistent
with previously described levels of cholesterol depletion
(Friedrichson and Kurzchalia, 1998; Green et al., 1999; Keller
and Simons, 1998; Sheets et al., 1999; Varma and Mayor,
1998). MCD had no effect on CD81 and CD9 expression, as
determined using mAbs 4.1F12 and MT81, but strongly
reduced MT81w labeling (Fig. 6A). We further quantified this
effect by flow cytometry analysis. Whereas MCD treatment
had no effect on CD81 and CD9 surface expression, cholesterol
depletion induced a significant reduction (40-50%) in MT81w
binding (Fig. 6B, upper panels). To test whether this was
specifically due to the removal of cholesterol, we analyzed the
effects of preformed MCD-cholesterol complexes, which are
known to replenish cells with cholesterol (Christian et al.,
1997). Cholesterol replenishment of cholesterol-depleted
Hepa1-6 cells reversed the effect of MCD on MT81w
binding, thereby confirming the specificity of the MCD
effects (Fig. 6B, middle panels). Furthermore, an increase in
MT81w binding was observed when cells were treated with
MCD-cholesterol without prior cholesterol depletion (Fig.
6B, lower panels). Taken together, these results demonstrate a
role of cholesterol in the organization of tetraspanin
microdomains.
CD81 in tetraspanin-enriched microdomains supports
infection by P. yoelii sporozoites
We have previously reported that hepatocyte CD81 is required
for infection by P. falciparum and P. yoelii sporozoites (Silvie
et al., 2003). As shown in Fig. 7A, MT81w efficiently inhibited
P. yoelii invasion of Hepa1-6 cells, which normally support P.
yoelii sporozoite invasion and exoerythrocytic development
(Mota and Rodriguez, 2000), in a concentration-dependent
manner (Fig. 7A). This shows that the fraction of CD81
associated with tetraspanin-enriched microdomains contributes
to infection by P. yoelii sporozoites. However, MT81w was not
as efficient as MT81 in blocking infection. MT81 could almost
completely block sporozoite invasion (>95% inhibition),
whereas MT81w induced a maximal inhibition of 60-70%. The
blocking efficiency of MT81w was increased when cells were
pretreated with MCD-cholesterol complexes (Fig. 7B).
Importantly, both mAbs also inhibited P. yoelii sporozoite
invasion of primary mouse hepatocytes, with a similar
efficiency to that seen with Hepa1-6 cells (data not shown).
The molecular determinants responsible for interactions
between tetraspanins, and thus for their localization into
tetraspanin microdomains, still remain elusive. However, it has
been shown that palmitoylation-deficient mutants of CD9 and
CD151 associate to a lower extent with other tetraspanins as
compared to wild-type molecules (Berditchevski et al., 2002;
Charrin et al., 2002; Yang et al., 2002). To determine whether
CD81 palmitoylation is required for its ability to support P.
yoelii sporozoite infection, Hepa1-6 cells were transfected with
wild-type human CD81 (hCD81) or palmitoylation-defective
human CD81 (hCD81plm) constructs, and infected with P.
yoelii sporozoites in the presence of MT81 mAb to block
endogenous mouse CD81. As shown in Fig. 8, expression of
Fig. 5. Precipitation of tetraspanins by digitonin. Biotin-labeled
Hepa1-6 cells were lysed in 1% Brij 97 and the lysates were treated
with digitonin (digit. +) or with vehicle alone as a control (–). After
elimination of the precipitated material, the supernatants were used
for immunoprecipitation using anti-CD81 mAbs MT81 and MT81w
or anti-5 integrin (5-int.). The panels are from the same
membranes and were given the same exposure.
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both wild-type and palmitoylation-defective CD81 restored
infection of MT81-treated cells, demonstrating that CD81
palmitoylation is dispensable during P. yoelii sporozoite
infection. The infection of fewer cells with hCD81plm as
compared to hCD81 was probably due to a lower surface
expression in transfected cells, as shown by FACS analysis
after labeling with the anti-CD81 mAb TS81 (MFI 56 versus
154 with hCD81plm and hCD81, respectively). Similar results
were obtained in HepG2 cells (data not shown).
Host cell membrane cholesterol is necessary for P. yoelii
and P. falciparum sporozoite invasion
If CD81 localization in tetraspanin microdomains is important
for its function during hepatocyte infection by sporozoites,
Fig. 6. CD81 localization in
tetraspanin-enriched
microdomains depends on
cholesterol. (A) Hepa1-6 cell
monolayers were treated with 10
mM MCD for 15 minutes at
37°C (or left untreated as a
control) before fixation and double
labeling with anti-CD9 mAb
4.1F12 (right panel) and anti-
CD81 mAbs MT81 or MT81w
(left panel). Bars, 40 m. (B)
Flow cytometry analysis of
Hepa1-6 cells stained with the
anti-CD81 mAbs MT81 and
MT81w or the anti-CD9 mAb
4.1F12. Upper panels: cells were
treated with MCD (thick black
line) or left untreated (thin black
line). Middle panels: cells were
treated with MCD (thin black
line) followed by
MCD/cholesterol (thick black
line). Lower panels: cells were
treated with MCD/cholesterol
(thick black line) or left untreated
(thin black line).
Fig. 7. Microdomain-associated CD81 supports P. yoelii sporozoite
infection. (A) Effects of increasing concentrations of mAbs MT81
(solid squares) and MT81w (open squares) on P. yoelii infection of
Hepa1-6 cells, expressed as the mean percentage of inhibition in
triplicate wells (± s.d.). (B) Untreated (control) and
MCD/cholesterol treated Hepa1-6 cells were infected with P. yoelii
sporozoites in the presence of MT81 and MT81w mAbs. Results are
expressed as the mean percentage inhibition in triplicate wells (±
s.d.), as compared to wells without mAbs.
Fig. 8. CD81 palmitoylation is dispensable for P. yoelii sporozoite
infection. Hepa1-6 cells were transfected with plasmids coding for
wild-type human CD81 (hCD81) or palmitoylation-defective human
CD81 (hCD81plm), or with the vector alone (mock), 24 hours before
infection with P. yoelii sporozoites in the presence of MT81 as
indicated. The number of exo-erythrocytic form (EEF)-infected cells
(mean ± s.d.) was determined as described in the Materials and
Methods section.
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then cholesterol depletion should inhibit, to some extent, the
level of infection, since as shown above it affects the
organization of surface tetraspanin microdomains. Hepa1-6
cells were treated with MCD prior to inoculation with P.
yoelii sporozoites. MCD treatment resulted in a reduction in
the number of EEF-infected cells by 40-60% depending on the
experiment (Fig. 9A). Interestingly, this inhibition was of the
same magnitude as the reduction of MT81w binding following
treatment with MCD (Fig. 6B). Inhibition of infection was
specifically due to cholesterol removal from the cell surface
since it was completely reversed by cholesterol replenishment
before sporozoite inoculation. Cholesterol removal was
effective in preventing P. yoelii infection because of inhibition
of sporozoite entry into MCD-treated Hepa1-6 cells, as
evidenced by counting intracellular sporozoites 3 hours after
parasite inoculation (Fig. 9B). Interestingly, treatment of cells
with MCD-cholesterol complexes without prior cholesterol
depletion enhanced infection (Fig. 9C). Furthermore,
treatment of Hepa1-6 cells with MCD or MCD-cholesterol
after completion of sporozoite invasion had no effect on
infection (Fig. 9C), confirming that the host membrane
cholesterol is required at the invasion step, and clearly
demonstrating that MCD is not toxic under the experimental
conditions used here. We also tested the role of cholesterol
during infection of primary mouse hepatocytes by P. yoelii
sporozoites. As shown in Fig. 9D, cholesterol depletion by
MCD inhibited hepatocyte infection by P. yoelii sporozoites,
and as seen with Hepa1-6 cells this effect was completely
reversed by cholesterol replenishment before sporozoite
inoculation.
We have reported previously that invasion of hepatocytes by
the human parasite P. falciparum can be specifically blocked
by anti-CD81 but not anti-CD9 antibodies (Silvie et al., 2003).
To directly assess whether expression of CD81 is essential for
P. falciparum infection, as for P. yoelii, we used RNA
interference to knock-down CD81 expression in primary
human hepatocytes in vitro. We could achieve ~50% reduction
of CD81 surface expression using a small interfering RNA
(siRNA) targeting CD81 (Fig. 10A). CD9 expression was not
affected by the CD81 siRNA, showing the specificity of
silencing. The reduced expression of CD81 led to an inhibition
of P. falciparum sporozoite infection of the same magnitude
(Fig. 10B). As a control, a siRNA targeting CD9 had no effect
Fig. 9. Host cholesterol is required for P. yoelii sporozoite invasion.
(A-C) Hepa1-6 cells were treated with MCD followed by
MCD/cholesterol when indicated, before infection by P. yoelii
sporozoites and quantification of exo-erythrocytic forms (EEFs) at 24
hours (A) or intracellular sporozoites at 3 hours (B). (C) Cells were
treated either before (black bars) or 3 hours after (open bars)
infection by sporozoites. (D) Primary mouse hepatocytes were
treated with MCD followed by MCD/cholesterol when indicated
before infection with P. yoelii sporozoites. The number of infected
cells was determined as described in the Materials and Methods
section. **P<0.01, as compared to untreated control.
Fig. 10. CD81 and cholesterol are required for P. falciparum
sporozoite invasion of human hepatocytes. (A) Primary human
hepatocytes transfected with a siRNA oligonucleotide targeting
CD81 (siCD81) or with a control siRNA (cont) were stained with
anti-CD81 (mAb TS81, left panel) or anti-CD9 (mAb TS9, right
panel) and analyzed by flow cytometry. (B) Quantification of P.
falciparum exo-erythrocytic forms (EEFs; mean of triplicate wells ±
s.d.) in human hepatocytes transfected with siRNA oligonucleotides
targeting CD81 (siCD81) or CD9 (siCD9), or with a control siRNA
(control). *P<0.05 as compared to control. (C) Primary human
hepatocytes were treated with MCD followed by
MCD/cholesterol, when indicated, before infection by P.
falciparum sporozoites. The number of EEF-infected cells was
determined as described in the Materials and Methods section.
**P<0.01, as compared to untreated control.
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on infection, although it reduced by ~40% the surface
expression of CD9 (data not shown). Together, these results
provide additional evidence for the specific role of CD81
during P. falciparum sporozoite invasion. We then analyzed the
effects of MCD-mediated cholesterol depletion on infection
of primary human hepatocytes by P. falciparum sporozoites.
As seen with P. yoelii, MCD inhibited P. falciparum
sporozoite invasion by up to 75%, and this effect was fully
reversed by cholesterol replenishment of cholesterol-depleted
hepatocytes (Fig. 10C), indicating a role for the host membrane
cholesterol also in P. falciparum sporozoite infection.
Cholesterol and CD81 are functionally linked during
Plasmodium sporozoite infection
So far, our data demonstrate that, (1) CD81 molecules
associated with the tetraspanin web participate in sporozoite
invasion, (2) cholesterol contributes to the organization of
tetraspanin microdomains on the cell surface and (3) both
CD81 and cholesterol are required on the host cell surface for
sporozoite infection. Taken together these observations suggest
that cholesterol is required during sporozoite invasion through
the assembly of tetraspanin microdomains and that the effects
of cholesterol depletion on infection are due to the
disorganization of these microdomains. To obtain further
evidence that the role of cholesterol is linked to CD81 during
sporozoite invasion, we tested the effect of cholesterol
depletion on CD81-independent infection by the rodent
parasite P. berghei. In contrast to P. yoelii, sporozoites from P.
berghei can infect CD81-deficient mouse hepatocytes (Silvie
et al., 2003), as well as human hepatocarcinoma HepG2 cells
(Hollingdale et al., 1983), which do not express CD81
(Berditchevski et al., 1996; Charrin et al., 2001). As shown in
Fig. 11A, MCD treatment had no effect on P. berghei
sporozoite invasion of HepG2 cells. To rule out a low efficiency
of MCD-mediated cholesterol depletion in HepG2 cells, we
repeated the experiments using HepG2 cells stably expressing
CD81 (HepG2/CD81), which support P. yoelii sporozoite
invasion and exo-erythrocytic development (Silvie et al., in
press). Infection of HepG2/CD81 cells by P. yoelii was
inhibited by MCD treatment, showing that MCD is efficient
in depleting cholesterol (Fig. 11B). Inhibition was fully
reversed by cholesterol replenishment prior to sporozoite
inoculation, confirming the specificity of MCD effects. By
contrast, P. berghei invasion of HepG2/CD81 was not affected
by MCD-mediated cholesterol depletion, as observed with
the parental CD81-negative HepG2 cells (Fig. 11C). By
showing that cholesterol is required only for sporozoite
invasion through the CD81-dependent pathway, our results
unravel a functional link between cholesterol and CD81 during
Plasmodium sporozoite entry.
Discussion
Use of mAbs to dissect the tetraspanin web in live cells
One remarkable feature of tetraspanins is their ability to act as
molecular organizers of specific proteo-lipidic membrane
microdomains (Charrin et al., 2003b; Charrin et al., 2003c;
Hemler, 2003; Levy and Shoham, 2005). These tetraspanin
microdomains display a number of critical differences that
distinguish them from conventional lipid rafts, such as their
disruption by Triton X-100 at 4°C and conversely their
maintenance during cell lysis at 37°C in milder detergents such
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as Brij 97 (Charrin et al., 2003b; Claas et al., 2001). Also, the
composition of tetraspanin microdomains differs from that of
lipid rafts. For instance, typical raft resident proteins such as
GPI-linked proteins and caveolin do not associate with
tetraspanins (Berditchevski et al., 2002; Charrin et al., 2003c;
Claas et al., 2001).
Recently, it became evident that antibodies recognizing
subpopulations of tetraspanin molecules could be useful to
analyze the tetraspanin web, notably on live cells. For example,
the binding of two anti-tetraspanin antibodies is modulated by
the expression of molecular partners. The anti-CD151 mAb
TS151r only binds to CD151 when it is not associated with
31 or 61 integrins (Kazarov et al., 2002; Serru et al.,
1999; Sterk et al., 2002), whereas the binding of the anti-CD9
mAb PAINS13 depends both on the expression of the integrin
6 subunit and on the activation of the 1 integrin subunit
(Gutierrez-Lopez et al., 2003). Here, we describe a new anti-
mouse CD81 mAb, named MT81w (for mouse tetraspanin
CD81 ‘web’), which specifically recognizes CD81 associated
with other tetraspanins. This is evidenced by the lack of
recognition of CD81 after cell lysis with detergents that do not
preserve tetraspanin-tetraspanin interactions, and by the
Fig. 11. Cholesterol and CD81 are functionally linked during
Plasmodium sporozoite invasion. HepG2 (A) or HepG2/CD81 cells
(B,C) were treated with MCD followed by MCD/cholesterol
when indicated before infection by P. berghei (A,C) or P. yoelii (B)
sporozoites. The number of exo-erythrocytic form (EEF)-infected
cells was determined as described in the Materials and Methods
section. **P<0.01, as compared to untreated control.
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complete removal of the CD81 pool recognized by MT81w
following immunodepletion of tetraspanin complexes.
Additional studies will be required to determine the molecular
basis of MT81w-restricted specificity. Even though the slope
of MT81w binding curve is very similar to that of MT81,
MT81w may be a low-affinity antibody that binds to CD81
bivalently, and thus would bind preferentially to CD81
molecules clustered within tetraspanin microdomains.
Alternatively, MT81w may recognize an epitope on CD81
induced by CD81 localization within tetraspanin-enriched
microdomains. This epitope may be induced as a consequence
of the interaction with other tetraspanins or with cholesterol. It
is very unlikely that MT81w could recognize CD81 associated
with cholesterol outside tetraspanin-microdomains, because
there is a tight correlation between association of tetraspanins
with other tetraspanins and association with cholesterol
(Charrin et al., 2003c), and all the CD81 fraction recognized
by MT81w is associated with CD9. Whatever the molecular
basis for MT81w specificity is, our data demonstrate that this
antibody is a valuable tool that can be used as a marker for
CD81 association with the tetraspanin web. In this regard, we
have found that a major fraction of CD81 associates with the
tetraspanin web in mouse hepatoma Hepa1-6 cells, and also in
primary mouse hepatocytes, where MT81w labeling was at 55-
75% that of MT81 (data not shown). Conversely, MT81w
labeling was lower in embryonic fibroblasts (30% of MT81,
Fig. 2) and much lower in mouse fibroblastic LM cells (3% of
MT81, data not shown). These observations suggest that a high
level of CD81 engagement into the tetraspanin web may
constitute a specific feature of hepatocytic cells as compared
to other cell types.
Cholesterol and tetraspanin microdomains
Although membrane cholesterol directly associates with
tetraspanins (Charrin et al., 2003c), its role in the assembly of
tetraspanin microdomains has remained unclear. Tetraspanin-
tetraspanin interactions (notably CD81-CD9) are not readily
disrupted upon MCD treatment of intact cells (Charrin et al.,
2003b; Charrin et al., 2003c; Claas et al., 2001). By contrast,
cell lysis in the presence of MCD results in a significant
disruption of tetraspanin-tetraspanin interactions (Charrin et
al., 2003c). Also, MCD treatment strongly reduces the
amount of tetraspanin complexes recovered in the light
membrane fractions of sucrose gradients (Claas et al., 2001;
Delaguillaumie et al., 2004). In one study, it was shown that
this phenomenon can result from the shedding of tetraspanin
microdomains from the cell membrane induced upon MCD
treatment (Claas et al., 2001). Here, using MT81w as a marker
for tetraspanin-tetraspanin interactions, we provide clear
evidence that the membrane cholesterol regulates the
organization of cell surface tetraspanin microdomains. Indeed,
the binding of MT81w to cells decreased after MCD-
mediated cholesterol depletion, and increased following
cholesterol cell loading. Importantly, in our experimental
conditions (using 10 mM MCD, for 15 minutes at 37°C),
there was no significant shedding of tetraspanin microdomains
induced by MCD, as evidenced by no reduction of surface
expression of either CD9 or CD81. However, we noticed that
increasing the concentration or the duration of MCD
treatment could eventually cause a reduction of surface
expression of both CD81 and CD9 (up to 30%), which was not
reversed by the back-addition of cholesterol and thus is
consistent with a loss of tetraspanins from the plasma
membrane.
The observation that MCD directly affects cell surface
tetraspanin microdomains, as evidenced by the reduction of
MT81w labeling, without inducing major changes in
tetraspanin-tetraspanin interactions observable by biochemical
methods (Charrin et al., 2003c; Claas et al., 2001), may be
explained by the existence of different levels of organization
of tetraspanin microdomains (Claas et al., 2001). On one level,
tetraspanins may interact with each other through a mechanism
that is not affected by MCD treatment of live cells. This level
of interaction is likely to involve membrane cholesterol since
these complexes can be disrupted with a Brij 97 lysis buffer
supplemented with MCD (Charrin et al., 2003c). We propose
that on a second level these complexes cluster into higher order
structures, through a mechanism affected by MCD treatment
of live cells. The existence of a MCD-resistant level of
interaction between tetraspanins would explain why the effect
of MCD on live cells is not detectable through biochemical
approaches, but is uncovered using labeling with the mAb
MT81w.
There are some lines of evidence suggesting that the MCD-
sensitive second level corresponds to a functional level of
tetraspanin microdomain organization. In one study, MCD
treatment of B lymphoid cells was found to inhibit tyrosine
phosphorylation induced upon ligation of tetraspanins,
whereas, on the contrary, addition of cholesterol enhanced
phosphorylation induced by tetraspanin engagement (Charrin
et al., 2003c). In another study, all functional effects linked to
CD82 engagement were abolished or strongly reduced in
MCD-treated Jurkat T cells (Delaguillaumie et al., 2004).
Tetraspanin microdomains and infection by intracellular
pathogens
Previous studies have shown that the host membrane
cholesterol is required for infection by erythrocytic stages of
Plasmodium (Lauer et al., 2000; Samuel et al., 2001), and also
by tachyzoites of Toxoplasma gondii, a distant relative of
Plasmodium (Coppens and Joiner, 2003). Interestingly, the
parasitophorous vacuole membrane of Plasmodium
erythrocytic stages and also Toxoplasma was found to be
enriched in raft components (Lauer et al., 2000; Mordue et al.,
1999), suggesting that these parasite stages may use
conventional lipid rafts for cell entry. Here, we show that
membrane cholesterol is also necessary during host cell
infection by P. yoelii and P. falciparum sporozoites, as
evidenced by the inhibition of infection resulting from
cholesterol depletion induced by MCD. Membrane
cholesterol is needed for sporozoite invasion, as shown by the
inhibition of P. yoelii sporozoite entry into MCD-treated cells
and by the absence of inhibition when cells were treated with
MCD after completion of invasion.
Several elements suggest that the effect of MCD on
sporozoite invasion is the consequence of an alteration of
tetraspanin-enriched microdomains. First, MCD affects the
organization of tetraspanin microdomains, as judged by the
reduction of MT81w binding. Interestingly, the inhibition of P.
yoelii infection of Hepa1-6 cells was of the same magnitude as
the reduction of MT81w binding. Also, addition of cholesterol
induced a significant enhancement of both infection and
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MT81w binding, again showing a correlation between the level
of CD81 engagement into microdomains and the level of
infection. Second, our data demonstrate that CD81 in
microdomains participates in infection, since the mAb MT81w,
which only binds to CD81 associated with tetraspanins, inhibits
P. yoelii infection. The lower inhibition achieved with saturating
concentrations of MT81w, as compared with MT81, seems to
conflict with an essential role of tetraspanin microdomains in
the invasion process. However, it is noteworthy that MT81w
does not recognize all the CD81 molecules present in the
microdomains, as suggested by the difference between MT81w
surface labeling (40-60% of total CD81 surface expression) and
the level of CD81 association (~85%, as determined by the CD9
immunodepletion experiment). Therefore, the partial inhibition
of infection achieved with MT81w is not inconsistent with a
major, and possibly, exclusive role of microdomain-associated
CD81 during sporozoite infection, since it could simply reflect
the partial recognition of this fraction of CD81 by MT81w. The
higher degree of inhibition of infection achieved with MT81w
when cells are pretreated with MCD-cholesterol complexes is
consistent with this hypothesis. Also, the ability of
palmitoylation-defective CD81 to support infection by P. yoelii
does not preclude an essential role of tetraspanin microdomains
in the invasion process since palmitoylation is not the only
mechanism by which tetraspanins interact with each other
(Berditchevski et al., 2002; Charrin et al., 2002; Yang et al.,
2002).
Although P. yoelii and P. berghei are closely related parasites
behaving very similarly in most aspects of sporozoite biology,
only P. yoelii requires CD81 to infect hepatocytes (Silvie et al.,
2003). The present study demonstrates that the two rodent
parasites also display a differential requirement of host cell
membrane cholesterol for invasion. By showing that
cholesterol is required only in the case of CD81-dependent
sporozoite infection, our results clearly indicate a functional
link between CD81 and cholesterol, and strongly suggest that
CD81 localization in tetraspanin microdomains is essential for
sporozoite infection.
Additional studies will be required to elucidate the
mechanisms involving tetraspanin microdomains during
Plasmodium sporozoite invasion of hepatocytes. In the absence
of evidence of a direct interaction between sporozoites and
CD81, and given the ability of CD81 to associate with multiple
proteins within the tetraspanin web, one can speculate that
CD81 may actually associate with one or several hepatocyte
receptors for the parasite. Previous studies have shown that
association with tetraspanins up-regulates the ligand binding
activity of partner proteins (Feigelson et al., 2003; Iwamoto et
al., 1994; Lammerding et al., 2003; Nishiuchi et al., 2005). If
CD81 associates with a receptor for Plasmodium, then CD81-
dependent clustering of this receptor into tetraspanin
microdomains could be essential to enable high avidity
interactions with parasite ligands at the entry junction.
Alternatively, CD81 engagement into microdomains may be
essential for some signaling events required at the time of
sporozoite invasion, or the host plasma membrane in
tetraspanin microdomains may display specific structural
properties required during the formation of the parasitophorous
vacuole.
Interestingly, CD81 is a receptor for the hepatitis C virus
(HCV) (Bartosch et al., 2003; Pileri et al., 1998; Zhang et al.,
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2004), and recent reports have pointed to a role for cholesterol
during host cell infection by HCV pseudoparticles (HCVpp).
In one study, MCD treatment of Huh-7 or Hep3B human
hepatocarcinoma cells specifically inhibited infection by
HCVpp (Zhang et al., 2004). In another study, high-density
lipoproteins (HDL) but not low-density lipoproteins (LDL) nor
lipid-free HDL apolipoproteins were shown to markedly
enhance HCVpp entry into Huh-7 cells, through a mechanism
dependent on the scavenger receptor BI (SR-BI) (Voisset et al.,
2005). In liver cells, SR-BI functions as a lipoprotein receptor
responsible for the selective uptake of cholesteryl ester from
HDL (Connelly and Williams, 2004). Based on these
observations, it will be interesting to see whether the clustering
of CD81 into cholesterol-dependent microdomains is also
essential for HCV infection.
In conclusion, our study demonstrates that membrane
cholesterol mediates the localization of CD81 into tetraspanin-
enriched microdomains and contributes to CD81-dependent
infection by Plasmodium sporozoites. Thus, tetraspanin
microdomains constitute a novel type of lipid-rich membrane
microdomain that could be used by pathogens for infection.
More generally, the cell membrane cholesterol has been shown
to be essential in a number of biological processes, notably
through the use of MCD-induced cholesterol depletion. The
fact that MCD affects tetraspanin microdomains raises the
possibility that some of these cholesterol-dependent processes
may actually involve tetraspanin microdomains.
Materials and Methods
Antibodies
Anti-human CD9 mAb TS9 and anti-human CD81 mAb TS81 (Charrin et al., 2001)
were from Diaclone (Besançon, France). Anti-mouse CD9 mAb 4.1F12 was
described previously (Le Naour et al., 2000). Anti-mouse 5 integrin mAb MFR5
was from BD Pharmingen (Le Pont de Claix, France). For generation of MT81 and
MT81w, a rat was injected intraperitoneally twice with 107 L-CD9 cells and a final
booster was given 3 weeks later with CD9-containing complexes collected from a
Brij 97 lysate of ~109 L-CD9 cells. Spleen cells were fused with P3x63AG8 mouse
myeloma cells to generate hybridomas according to standard techniques.
Plasmids
A human CD81 mutant lacking five cysteines representing potential palmitoylation
sites (triple mutant) has been previously described (Clark et al., 2004). A sixth
cysteine, located in the second transmembrane domain of CD81, was mutated using
the QuickChangeTM site-directed mutagenesis kit from Stratagene (Amsterdam, The
Netherlands), according to the manufacturer’s specifications, resulting in a CD81
mutant lacking all potential palmitoylation sites (CD81plm).
Parasites and cells
P. yoelii (265BY strain), P. berghei (ANKA strain) and P. falciparum (NF54 strain)
sporozoites were obtained from dissection of infected Anopheles stephensi mosquito
salivary glands. Mouse hepatoma cells Hepa1-6 (ATCC CRL-1830), human cervical
carcinoma cells HeLa (ATCC CCL-2) and mouse fibroblastic LM cells stably
expressing human CD9 (L-CD9) (Rubinstein et al., 1994) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Cergy Pontoise, France)
supplemented with 10% fetal calf serum (FCS; Biowest, Nuaillé, France), 2 mM
glutamine, 50 g/ml penicillin, 50 g/ml streptomycin and 100 g/ml neomycin
(Invitrogen). Human hepatocarcinoma cells HepG2 and HepG2 stably expressing
CD81 (HepG2/CD81) (Bartosch et al., 2003) were a kind gift from F. L. Cosset,
and were cultured in DMEM supplemented as above, in culture dishes coated with
rat tail collagen I (Becton-Dickinson, Le Pont de Claix, France). Primary mouse
hepatocytes were isolated as described previously (Renia et al., 1990) and cultured
in William’s E medium (Invitrogen) supplemented as above. Primary human
hepatocytes were isolated and cultured as described previously (Silvie et al., 2004).
Mouse embryonic fibroblasts were generated from E15 embryos from wild-type,
CD9 (Le Naour et al., 2000) and CD81 (Maecker and Levy, 1997) knockout mice,
according to a previously described procedure (Wurst and Joyner, 1993).
Sporozoite invasion assay
Hepa1-6 or HepG2 cells (15104 per well), or primary mouse (9104 per well) or
human (18104 per well) hepatocytes were seeded in 8-chamber plastic Lab-Tek
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slides (Nalge Nunc International, Cergy Pontoise, France), 24-48 hours (except for
human hepatocytes, 3-7 days) prior to inoculation with sporozoites (1105 parasites
per well, except for P. berghei, 3104 parasites per well). After 3 hours at 37°C,
cultures were washed and further incubated in fresh medium for 24-48 hours (P.
yoelii and P. berghei) or 72 hours (P. falciparum) before quantification of infected
cells (containing an EEF in their cytoplasm) in triplicate wells by
immunofluorescence, as described previously (Silvie et al., 2003). Quantification of
intracellular sporozoites was carried out 3 hours post-infection using a double
immunostaining technique (Silvie et al., 2002). For antibody-mediated inhibition
assays, mAbs (25 g/ml, unless otherwise stated) were added to the cultures at the
time of sporozoite inoculation and removed 3 hours later. Inhibition results were
analyzed for statistical significance using the one-way ANOVA followed by the
Tukey multiple comparison test.
Immunofluorescence labeling
For flow cytometric analysis, cells were detached using a non-enzymatic solution
(Invitrogen), washed and stained with saturating concentrations (unless otherwise
specified) of primary mAb. After washes in culture medium, cells were incubated
with 10 g/ml FITC-labeled secondary antibody (Beckman Coulter, Villepinte,
France), washed again three times and fixed with 1% formaldehyde in PBS. All
incubations were performed for 30 minutes at 4°C. Analysis of cell-surface staining
was performed using a FACScalibur flow cytometer (Becton-Dickinson, San Jose,
CA, USA). For fluorescence microscopy, cells were fixed in paraformaldehyde and
incubated with anti-CD9 mAb 4.1F12 coupled to Alexa Fluor 488 and biotin-
conjugated MT81 or MT81w followed by incubation with streptavidin-Alexa Fluor
594, before examination with a Leica DMR fluorescence microscope equipped with
an appropriate set of filters.
Small interfering RNA and plasmid transfection
We used small double stranded RNA oligonucleotides targeting mouse CD81 (5-
CGT GTC ACC TTC AAC TGT A-3), mouse CD9 (5-GAG CAT CTT CGA GCA
AGA GAA-3), human CD81 (5-CAC GTC GCC TTC AAC TGT A-3) or human
CD9 (5-GAG CAT CTT CGA GCA AGA A-3). A siRNA oligonucleotide
targeting human CD53 (5-CAA CTT CGG AGT GCT CTT C-3) was used as a
control siRNA throughout the study. Hepa1-6 cells (5-10106 cells in 400 l
RPMI) were transfected with 200 pmol of siRNA by electroporation (Weil et al.,
2002) using the Gene Pulser apparatus (Bio-Rad, Ivry, France). Human hepatocytes
were transfected with siRNA using the Lipofectamine 2000 reagent (Invitrogen),
according to the manufacturer’s recommendations. Following siRNA transfection,
cells were cultured for 48 hours before flow cytometry analysis or sporozoite
infection. Plasmid transfections were performed using the Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s specifications.
Immunoprecipitation
Surface labeling of cells with EZ-link-Sulpho-NHS-LC-biotin (Pierce, Rockford,
IL, USA) was performed as described previously (Charrin et al., 2001). Biotin-
labeled and non-labeled cells were lysed at 4°C for 30 minutes in 10 mM Tris, pH
7.4, 150 mM NaCl, 0.02% NaN3, protease inhibitors and either 1% Brij 97 (Sigma),
1% digitonin (high purity; Calbiochem, San Diego, CA, USA), 1% CHAPS (Roche
Applied Science, Meylan, France) or 1% Triton X-100 (Roche Applied Science).
Immunoprecipitations were then performed using protein G-Sepharose beads
(Amersham Biosciences, Rainham, Essex, UK), as described previously
(Berditchevski et al., 1996; Charrin et al., 2001). For precipitation of cholesterol
with digitonin, a 1/10th volume of 10% digitonin in methanol, or methanol as a
control, was added to the Brij 97 supernatants. After 30 minutes at 4°C, the insoluble
material was removed by centrifugation at 12,000 g, and the supernatant was used
for immunoprecipitation as above. The immunoprecipitates were separated by SDS-
PAGE (5–15% gel) under non-reducing conditions and transferred to a PVDF
membrane (Amersham Biosciences). Biotin-labeled surface proteins were revealed
using streptavidin-biotinylated horseradish peroxidase complex (Amersham
Biosciences) revealed by enhanced chemiluminescence (Perkin Elmer Life
Sciences, Zaventem, Belgium). Western blotting on immunoprecipitates was
performed using biotinylated mAbs, followed by streptavidin-biotinylated
horseradish peroxidase complex and visualization by enhanced chemiluminescence.
Cholesterol depletion
Cholesterol depletion was carried out by incubating cell monolayers with 10 mM
methyl--cyclodextrin (MCD; Sigma) in serum-free medium at 37°C for 15
minutes, as described previously (Charrin et al., 2003c). Treatment with MCD
removed ~40% of the cholesterol content of Hepa1-6 cells, as determined using the
Amplex Red cholesterol kit (Invitrogen-Molecular Probes) according to the
manufacturer’s instructions. Cholesterol replenishment of cholesterol-depleted cells
was achieved by incubating monolayers with 1:10 (mol/mol) complex of cholesterol
(Sigma) and MCD, using a 1 mM final cholesterol concentration, in serum-free
medium at 37°C for 15 minutes as described previously (Charrin et al., 2003c).
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